You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring Already a subscriber Login You have…
Lundbeck and Otsuka Pharmaceutical have announced that the FDA has determined that the supplementary New Drug Application (sNDA) for brexpiprazole for the use in the treatment of agitation associated with Alzheimer’s dementia (AAD) is sufficiently complete to permit a substantive review. The FDAlready a subscriber Login You have read all…
The company has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial being conducted at the Karolinska University Hospital. The aim of the dose escalation clinical trialAlready a subscriber Login…
SAGA Diagnostics has entered into an assay development agreement with AstraZeneca. SAGA Diagnostics will in the course of this agreement develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies. "We have chosen to partner with SAGA Already a subscriber Login You have read…
